RxDoctor Payments Data

Catherine Chua, DO

Family Medicine · Elkins, WVNPI 1295726685

Payments from drug & device makers

$494in general payments, 2019–2025

Across 12 payments — averaging $41.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$248
  • Pfizer$98
  • Novartis$90
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$23
  • Abbott$19
  • Dexcom, Inc.$17

What the payments were for

  • Food & beverage$494100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$494 in reported general payments places this provider in the 55th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$128,731
Medicare patients
352
Services billed
1,408

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban820$314,832
Invega SustennaPaliperidone Palmitate50$166,505
Aralast NpAlpha-1-Proteinase Inhibitor13$132,481
OzempicSemaglutide97$109,886
MounjaroTirzepatide84$84,311
XifaxanRifaximin44$71,376
Tresiba Flextouch U-200Insulin Degludec14$49,854
Budesonide174$45,163
XareltoRivaroxaban120$40,528
JanuviaSitagliptin Phosphate105$38,043
JardianceEmpagliflozin108$36,264
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog269$31,476
TrulicityDulaglutide40$27,726
Tresiba Flextouch U-100Insulin Degludec100$27,184
ArexvyRsvpref3 Antigen/As01e/Pf77$23,883

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$98$314,832820 claims
Novo NordiskOzempic, Tresiba$248$118,202120 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$23$71,37644 claims
NovartisEntresto$90$15,36730 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Elkins

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →